Glioblastoma Cell Models for Research

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, accounting for approximately 48.6% of all malignant brain tumors (CBTRUS 2023). The global incidence is about 3.2 per 100,000 person-years (WHO 2021). Despite multimodal therapy including surgical resection, radiotherapy, and temozolomide chemotherapy, the prognosis remains dismal with a median survival of 14-16 months and a 5-year survival rate of only 6.9% (NCI SEER 2023). Risk factors include exposure to ionizing radiation and rare genetic syndromes such as Li-Fraumeni and neurofibromatosis type 1. The disease is slightly more common in males and in older adults, with peak incidence between 65-75 years.

GBM is an ideal model for studying tumor heterogeneity, therapy resistance, and the tumor microenvironment. It is characterized by extensive intratumoral heterogeneity with multiple subclones harboring distinct genetic alterations. Public datasets such as TCGA-GBM and the GBM single-cell atlas provide rich molecular data. Open questions include the cellular origin, mechanisms of resistance to standard therapy, and the role of the immune microenvironment. Gene-edited cell models are essential for functional validation of candidate drivers and for developing targeted therapies.

Glioblastoma pathogenesis is driven by several core pathways:

• • Receptor Tyrosine Kinase (RTK) Signaling: Aberrant activation of EGFR, PDGFRA, and MET leads to downstream signaling.
• • PI3K/AKT/mTOR Pathway: Mutations in PTEN, PIK3CA, and PIK3R1 activate this pro-survival pathway.
• • p53 Pathway: TP53 mutations and MDM2 amplification disrupt cell cycle checkpoints.
• • RB Pathway: CDKN2A/B deletions and CDK4 amplification lead to uncontrolled cell proliferation.

These pathways are frequently altered in GBM, contributing to uncontrolled growth and therapy resistance.

Data from TCGA and COSMIC.

Key signaling networks deregulated in GBM include:

• • RTK/RAS/PI3K: EGFR, PDGFRA, MET, and downstream RAS and PI3K.
• • PI3K/AKT/mTOR: PTEN loss, PIK3CA mutations, and AKT activation.
• • p53/MDM2: TP53 mutations and MDM2 amplification.
• • RB/CDK4/6: CDKN2A/B loss and CDK4 amplification.
• • Wnt/β-catenin: Aberrant activation in a subset of GBM.
• • Notch: Altered signaling in glioma stem cells.

These networks interact to promote proliferation, survival, invasion, and stemness.

Common GBM cell lines and their key mutations:

Organoids (patient-derived organoids, PDOs) preserve tumor heterogeneity and 3D architecture, making them valuable for drug testing and studying the microenvironment.

Animal models for GBM include:

• • Patient-Derived Xenografts (PDX): Implantation of patient tumor cells into immunodeficient mice; retains patient-specific mutations.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockouts or knock-ins of common GBM mutations (e.g., EGFRvIII, PTEN loss) using Cre-lox systems.
• • Induced Models: Use of viral vectors or transposons to express oncogenes or silence tumor suppressors in specific brain regions.

These models are used for studying tumor initiation, progression, and testing novel therapies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockout of tumor suppressors or knock-in of oncogenic mutations. For example, a PTEN knockout U87MG cell line can be generated to study the effects of PTEN loss on PI3K pathway activation. Similarly, an EGFRvIII knock-in in U251MG cells can model the most common EGFR mutation. These isogenic pairs allow direct comparison of mutant vs. wild-type cells, eliminating confounding genetic background. Commercially available, sequence-verified gene-edited cell models accelerate research by providing validated tools for drug discovery and functional genomics.

Gene-edited cells are used to validate the function of genes implicated in GBM. For example, knocking out TP53 in a p53 wild-type cell line can reveal its role in cell cycle arrest and apoptosis. Knock-in of IDH1 R132H in a wild-type background can model the metabolic changes and epigenetic alterations seen in secondary GBM. These models help identify novel therapeutic targets.

Isogenic cell line pairs (e.g., EGFRvIII knock-in vs. wild-type) are used in high-throughput drug screens to identify compounds that selectively kill mutant cells. They also model acquired resistance: chronic exposure to a drug can select for resistant clones, and gene editing can introduce specific resistance mutations to study mechanisms. For example, a PTEN knockout line can be used to test PI3K inhibitors.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of a specific mutation. For instance, in PTEN-deficient GBM cells, knocking out other genes can reveal vulnerabilities that can be targeted therapeutically. Gene-edited models also help validate biomarkers for patient stratification.